Hengrui Medicine: A subsidiary received approval for clinical trials of HRS-2129 tablets. Currently, no drug with the same target has been approved for marketing in China.

A subsidiary received approval for clinical trials of HRS-2129 tablets. Currently, no drug with the same target has been approved for marketing in China.

September 30, 2025 Source: drugdu 165

According to the AI news of the China Business Network, on September 29, Hengrui Medicine (600276.SH) announced that its subsidiaries Shandong Shengdi Pharmaceutical Co., Ltd. and Shanghai Hengrui Medicine Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for HRS-2129 tablets, agreeing to conduct clinical trials for the indications of adult diabetic peripheral neuropathy pain and adult osteoarthritis pain. HRS-2129 tablets are intended for the treatment of acute and chronic pain. Currently, no drugs with the same target have been approved for marketing in China. As of now, the cumulative R&D investment in this project is approximately 112 million yuan. According to relevant laws and regulations, after obtaining the drug clinical trial approval notice, the drug must still conduct clinical trials and be reviewed and approved by the National Medical Products Administration before it can be produced and marketed.

https://finance.eastmoney.com/a/202509293526362066.html

By editor

A subsidiary received approval for clinical trials of HRS-2129 tablets. Currently, no drug with the same target has been approved for marketing in China.

Read more on

Trending Topics

Hot Tags

Subscribe

more

more

Customer Services

About Us

Buy on Drugdu.com

Sell on Drugdu.com

Blogroll

Free APP

Follow Us